SEC Tracker
Get the app

BioMarin Pharmaceutical BMRN

BioMarin Pharmaceutical FY 2024: revenue $2.9B, up 18%; diluted EPS $2.21

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers BioMarin Pharmaceutical reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$2.9B+18% from $2.4B in FY 202310-K income statement, on EDGAR
  2. Net income$426.9M+155% from $167.6M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS$2.21+154% from $0.87 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$942.8M+25% from $755.1M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations$572.8M+260% from $159.3M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when BioMarin Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  2. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025
  5. Prestige Consumer Healthcare PBH public float $3.0B, Sep 30, 2025